Literature DB >> 18477899

The risk of developing a second, different, cancer among 14 560 survivors of malignant cutaneous melanoma: a study by AIRTUM (the Italian Network of Cancer Registries).

Emanuele Crocetti1, Stefano Guzzinati, Eugenio Paci, Fabio Falcini, Roberto Zanetti, Marina Vercelli, Ivan Rashid, Vincenzo De Lisi, Antonio Russo, Susanna Vitarelli, Stefano Ferretti, Lucia Mangone, Rosaria Cesaraccio, Rosario Tumino, Fabio Pannozzo.   

Abstract

The aim of this study was to provide further quantitative data on the risk of second nonmelanoma cancers in patients with cutaneous malignant melanoma (CMM). A cohort of 14 560 population-based patients from the Italian Network of Cancer Registries incident during 1985-2002 were included and followed up for further incident cases and vital status. Standardized incidence ratios (SIR) were used to compare the number of observed second cancers with expected cancers. In a total of 69 581 person-years, 1020 second cancers were registered, of which 804.6 were expected (SIR=1.27; 95% confidence interval 1.19-1.35). The risk was similar for males and females, (SIR=1.27 and 1.26, respectively). The risk was slightly higher among younger (<60 years; SIR=1.44) than older (60+ years; SIR=1.19) patients. The overall risk in the period after CMM diagnosis did not change significantly (SIR=1.34 during the first 5 years and 1.12 afterwards). No differences in the overall risk were evident in different years of diagnosis, for different melanoma morphology types or for different geographical areas within Italy. Statistically significantly increased risks were found for nonmelanoma skin cancers [observed number (n)=362, SIR=3.12], for bone (n=5, SIR=6.08) and for kidney cancers (n=39, SIR=1.95) and lower than expected risks were found for liver (SIR=0.46) and lung cancers (SIR=0.71). We confirm that CMM patients are at high risk for nonmelanoma skin cancers. The reasons for the increased risk of kidney and bone cancers are not yet clear.

Entities:  

Mesh:

Year:  2008        PMID: 18477899     DOI: 10.1097/CMR.0b013e3282fafd0a

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  7 in total

1.  Mutual Risks of Cutaneous Melanoma and Specific Lymphoid Neoplasms: Second Cancer Occurrence and Survival.

Authors:  Megan M Herr; Sara J Schonfeld; Graça M Dores; Diana R Withrow; Margaret A Tucker; Rochelle E Curtis; Lindsay M Morton
Journal:  J Natl Cancer Inst       Date:  2018-11-01       Impact factor: 13.506

2.  Sun-protection behaviors of melanoma survivors.

Authors:  Deborah Mayer; Annah Layman; John Carlson
Journal:  J Am Acad Dermatol       Date:  2012-01       Impact factor: 11.527

3.  Risk of subsequent primary tumor development in melanoma patients.

Authors:  Veronika Tóth; Zsófia Hatvani; Beáta Somlai; Judit Hársing; János F László; Sarolta Kárpáti
Journal:  Pathol Oncol Res       Date:  2013-05-17       Impact factor: 3.201

4.  Risk factors for keratinocyte skin cancer in patients diagnosed with melanoma, a large retrospective study.

Authors:  Pablo Espinosa; Ruth M Pfeiffer; Zaida García-Casado; Celia Requena; Maria Teresa Landi; Rajiv Kumar; Eduardo Nagore
Journal:  Eur J Cancer       Date:  2015-12-17       Impact factor: 9.162

5.  On the roles of solar UV irradiance and smoking on the diagnosis of second cancers after diagnosis of melanoma.

Authors:  William B Grant
Journal:  Dermatoendocrinol       Date:  2012-01-01

6.  The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study.

Authors:  Danny R Youlden; Peter D Baade
Journal:  BMC Cancer       Date:  2011-02-23       Impact factor: 4.430

7.  Cancer Prevention for Survivors: Incidence of Second Primary Cancers and Sex Differences-A Population-Based Study from an Italian Cancer Registry.

Authors:  Rosalia Ragusa; Antonina Torrisi; Alessia Anna Di Prima; Antonietta A Torrisi; Antonella Ippolito; Margherita Ferrante; Anselmo Madeddu; Vincenzo Guardabasso
Journal:  Int J Environ Res Public Health       Date:  2022-09-26       Impact factor: 4.614

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.